Key Points
- Insider Kevin Patrick Danahy sold a total of 40,000 shares in two transactions (20,000 on Feb 9 at $21.45 for $429,000 and 20,000 on Feb 11 at $25.20 for $504,000), totaling about $933,000, and filings show his stake fell roughly 31.6% to 43,298 shares (valued ≈ $929k in the filing).
- Market and analyst context: PLSE traded around $25.25 (up ~5.6%) with a $1.71B market cap; analysts are mixed with a consensus "Hold" and an average price target of $26 (two Buys, one Sell).
Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) insider Kevin Patrick Danahy sold 20,000 shares of the business's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $21.45, for a total transaction of $429,000.00. Following the transaction, the insider owned 43,298 shares in the company, valued at approximately $928,742.10. This represents a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Kevin Patrick Danahy also recently made the following trade(s):
- On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $25.20, for a total value of $504,000.00.
Pulse Biosciences Trading Up 5.6%
PLSE opened at $25.25 on Thursday. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -22.35 and a beta of 1.77. Pulse Biosciences, Inc has a 1 year low of $12.56 and a 1 year high of $26.30. The stock has a fifty day moving average price of $14.97 and a 200 day moving average price of $15.66.
Wall Street Analyst Weigh In
A number of research firms recently commented on PLSE. Weiss Ratings restated a "sell (d-)" rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Mizuho set a $30.00 price target on shares of Pulse Biosciences in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Pulse Biosciences has a consensus rating of "Hold" and an average price target of $26.00.
View Our Latest Report on Pulse Biosciences
Institutional Investors Weigh In On Pulse Biosciences
Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock valued at $26,000 after purchasing an additional 680 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after buying an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Pulse Biosciences by 44.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company's stock valued at $79,000 after buying an additional 1,372 shares during the last quarter. KLP Kapitalforvaltning AS raised its holdings in Pulse Biosciences by 136.0% in the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company's stock worth $104,000 after acquiring an additional 3,400 shares during the period. Finally, AlphaQuest LLC lifted its position in Pulse Biosciences by 184.5% during the 2nd quarter. AlphaQuest LLC now owns 8,864 shares of the company's stock worth $134,000 after acquiring an additional 5,748 shares during the last quarter. Institutional investors own 76.95% of the company's stock.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
